NVCR News and Press, NovoCure Limited From 07/02/21

Mario13/E+ via Getty Images Arcturus wins new bullish call at Cantor on experimental COVID-19 shot Arcturus Therapeutics (ARCT) has added ~1.3% in the pre-market after Cantor Fitzgerald initiated its coverage with an overweight recommendation highlighting the company’s effort...

Gainers: Alterity Therapeutics Limited (ATHE) +68%.TRxADE HEALTH (MEDS) +57%.Marin Software (MRIN) +45%.Bridgeline Digital (BLIN) +35%.Birks (BGI) +25%.Pulse Biosciences (PLSE) +25%.SGOCO Group (SGOC) +22%.Grid Dynamics Holdings (GDYN) +19%.scPharmaceuticals (SCPH) +18%.U.S. Silica Holdi...

Shares of Novocure (NASDAQ: NVCR) were sliding 15.1% lower as of 11:05 a.m. EDT on Thursday. The decline came after the company announced final results from its phase 2 study evaluating a combination of its Tumor Treating Fields (TTFields) therapy with sorafenib in treating advanced...

Gainers: Alterity Therapeutics (ATHE) +103%, TRxADE HEALTH (MEDS) +62%, Pulse Biosciences (PLSE) +22%, Spero Therapeutics (SPRO) +12%, Kintara Therapeutics (KTRA) +6%.Losers: Citius Pharmaceuticals (CTXR) -21%, Aligos Therapeutics (A...

Borqs Technologies (BRQS) -17%.Verb Technology (VERB) -15%.CureVac (CVAC) -13% on final data from phase 2b/3 trial on COVID vaccine.1stdibs.Com (DIBS) -12%.Newegg Commerce (NEGG) -11%.Weidai (WEI) -11%.NovoCure (NVCR) -10% after final results from mid-stage TTFields liver ...

Disease control rate was 76% with 9.5% objective response in a patient population with poor prognosis and limited exposure to study treatments In patients who completed at least 12 weeks of Tumor Treating Fields treatment, disease control rate was 91% with 18% objective respon...

In 2020 alone, almost 10 million people lost their battle against cancer. However, oncology company NovoCure (NASDAQ: NVCR) and its new category of cancer treatment is improving the lives of patients. And with 1,100% gains since its IPO, it's also improving investors' lives....

Novocure (NVCR) announces that it has advanced a new, flexible torso array into a clinical usability study.The updated array will be tested by patients and their caregivers at four clinical sites in Europe.The new design is intended to improve skin adhesion, to increase degrees-of-motion...

New array intended to increase ease-of-use for torso and abdominal applications Novocure (NASDAQ: NVCR) today announced it has advanced a new, flexible torso array into a clinical usability study. The updated array will be tested by patients and their caregivers at four clin...

As it harnesses the power of an electromagnetic field, NovoCure offers hope to countless patients suffering from aggressive cancers. Tumor Treating Fields are now approved for deadly cancers, including glioblastoma multiforme and mesothelioma. The sales also are heading toward the blo...